When treating lung cancer, there’s one mutation that can rear its ugly head: Exon 20. The Hydra campaign beautifully illustrates the uncontrolled danger of Exon 20 mutations in advanced non-small cell lung cancer. Without multi-mechanistic approaches to treatment, this elusive menace will continue to wreak havoc in patients.